Uprze­jmie infor­mu­je­my, że NCBiR otworzył nabór wniosków w konkur­sie w ramach TRANSCAN‑3 ERA-NET. Celem inic­jaty­wy jest wzmoc­nie­nie współpra­cy między­nar­o­dowej w dziedzinie badań nad nowot­wora­mi.

Pier­wszy konkurs w ramach pro­gra­mu TRANSCAN‑3 (Joint Transna­tion­al Call 2021) obe­j­mu­je finan­sowanie pro­jek­tów z zakre­su nowej gen­er­acji immunoter­apii nowot­worów: Next gen­er­a­tion can­cer immunother­a­py: tar­get­ing the tumour microen­vi­ron­ment.

Szczegółowe infor­ma­c­je o konkur­sie:

Dla kogo
Mikrofir­ma,
Mała i śred­nia fir­ma,
Duża fir­ma,
Kon­sor­cjum,
Uczel­nia,
Jed­nos­t­ka naukowa.

Na co
Dofi­nan­sowanie moż­na przez­naczyć na real­iza­cję badań prze­mysłowych i prac roz­wo­jowych.

Part­nerzy
Aus­tria, Bel­gia, Esto­nia, Franc­ja, Hisz­pa­nia, Irlan­dia, Izrael, Kana­da, Łot­wa, Niem­cy, Nor­we­gia, Por­tu­galia, Rumu­nia, Słowac­ja, Węgry, Włochy, Tajwan, Tur­c­ja

Budżet konkur­su
1 200 000 euro na wszys­tkie pro­jek­ty z udzi­ałem pol­s­kich part­nerów;
Kurs EBC z dnia otwar­cia konkur­su, tj. 06.04.2021 r. – 4,5914 PLN

Har­mono­gram konkur­su
Data ogłoszenia konkur­su lub inic­jaty­wy: 06.04.2021 r.
Rozpoczę­cie naboru wniosków: 06 kwiet­nia 2021 r.
Zakończe­nie naboru wniosków: 29 czer­w­ca 2021 r.; godz. 12.00
Wyni­ki konkur­su – maj 2022
Pub­likac­ja listy rankingowej- maj 2022

 

Sposób składa­nia wniosków
Nabór wniosków między­nar­o­dowych odby­wa się poprzez sys­tem elek­tron­iczny, dostęp­ny od 20 kwiet­nia 2021 na między­nar­o­dowej stron­ie konkur­su: https://ptoutline.eu/app/transcan2021

W celu złoże­nia wniosku prosimy o kon­takt z Dzi­ałem Pro­jek­tów Między­nar­o­dowych Uni­w­er­syte­tu Medy­cznego w Łodzi.

Szczegółowe infor­ma­c­je na tem­at konkur­su dostęp­ne są na stron­ie NCBiRu[link: https://www.gov.pl/web/ncbr/transcan-3-era-net].

Zakres tem­aty­czny
“Next gen­er­a­tion can­cer immunother­a­py: tar­get­ing the tumour microen­vi­ron­ment”

 

Despite advances in immunother­a­pies, obsta­cles and chal­lenges, includ­ing lim­it­ed response rates, the inabil­i­ty to pre­dict clin­i­cal effi­ca­cy, and poten­tial side effects such as autoim­mune reac­tions or cytokine release syn­dromes, remain and hin­der fur­ther appli­ca­tions of immunother­a­pies in clin­ics. Thus, a deep­er under­stand­ing of the TME, able to dis­sect dis­tinct class­es and sub­class­es of it, is essen­tial for deci­pher­ing new mech­a­nisms of immunother­a­pies, defin­ing new pre­dic­tive bio­mark­ers, and iden­ti­fy­ing nov­el ther­a­peu­tic tar­gets. In the con­text of trans­la­tion­al research, this top­ic at the inter­sec­tion of lab­o­ra­to­ry and clin­i­cal research in immuno-oncol­o­gy will com­prise two gen­er­al aims which con­cur to the pos­si­ble clin­i­cal appli­ca­tions. Pro­pos­als will have to cov­er at least one of the six (6) spe­cif­ic sub-aims list­ed below. Approach­es should be direct­ed to draw up a mul­ti­di­men­sion­al TME map paving the road for new effi­ca­cious immunother­a­py strate­gies. Projects should be built from a sol­id and estab­lished hypoth­e­sis and should be rel­e­vant with regards to the pos­si­ble improve­ments in clin­i­cal prac­tice

Aim 1: Iden­ti­fi­ca­tion and val­i­da­tion of TME sub­class­es and their con­tri­bu­tion to the resis­tance mech­a­nisms: Trans­la­tion­al research using tumour sam­ples col­lect­ed from ret­ro­spec­tive and/or prospec­tive cohorts of patients.

1.1 Dis­sec­tion of tumour cell­s/­tu­mour-infil­trat­ing immune/stromal cells and iden­ti­fi­ca­tion of TME sub­class­es (sin­gle-cell analy­ses, mass cytom­e­try, imag­ing, mul­ti­di­men­sion­al immuno­his­to­chem­istry, etc.) for TME stud­ies (3D cul­ture sys­tems; patient-derived organoids; patient-derived xenografts; syn­gene­ic, genet­i­cal­ly mod­i­fied and chem­i­cal car­cino­gen­e­sis-induced mouse mod­els, etc.).

1.2 Def­i­n­i­tion of the con­tri­bu­tion of TME to resis­tance mech­a­nisms and iden­ti­fi­ca­tion of new ther­a­peu­tic tar­gets through mul­ti­omics (epige­nom­ic, tran­scrip­tom­ic, pro­teom­ic, metabolomics, study­of the micro­bio­me and virome, etc.) to assess func­tion­al char­ac­ter­is­tics of TME-tumour cell inter­play with­in the pri­ma­ry tumour and/or metas­tases (e.g the under­ly­ing sig­nal­ing, the tran­scrip­tion­al land­scape, the cell-cell com­mu­ni­ca­tion, the net­work reg­u­la­tion of immune cells, etc.), to iden­ti­fy can­di­date TME tar­gets and to assess the activ­i­ty of path­way-tar­get­ing agents.

1.3 Devel­op­ment of tools capa­ble of pre­dict­ing treat­ment effi­ca­cy and tumour recur­rence using min­i­mal­ly- or non­in­va­sive tech­niques (gen­er­a­tion of algo­rithms mod­el­ling the net­work dynam­ics, pre­dic­tive mod­els based on arti­fi­cial intel­li­gence, inte­grat­ing ‑omics data and net­work approach­es). Devel­op­ment of robust non­in­va­sive bio­mark­ers of dis­ease course (radiomics, cell-free cir­cu­lat­ing tumour DNA, miR­NA sig­na­tures, cir­cu­lat­ing tumour cells, etc.). Sex/gender impact must be con­sid­ered

Aim 2: Tar­get­ing TME to improve effi­ca­cy of immunother­a­py in human patients.

2.1 Devel­op­ment of new pre­ci­sion ther­a­peu­tic strate­gies that may pre­vent human tumour recur­rence or resis­tance (T‑cell-based can­cer immunother­a­pies, immune check­point block­ers (ICBs), chimeric anti­gen recep­tor (CAR)-T-cells, pre­ven­tive and ther­a­peu­tic vac­cines, etc.).

2.2 Eval­u­a­tion in trans­la­tion­al stud­ies of the impact of TME on treat­ment effi­ca­cy and patient out­come (clin­i­cal util­i­ty of spe­cif­ic TME fea­ture detec­tions or iden­ti­fi­ca­tions, clin­i­cal util­i­ty of spe­cif­ic intra­tu­mour or periph­er­al blood immune bio­mark­ers, sex/gender impact, etc.).

2.3 Phase I and II clin­i­cal tri­als (com­bi­na­tions of avail­able treat­ments, new ther­a­peu­tic strate­gies, new admin­is­tra­tion schemes, etc.) tar­get­ing, or pre­vent­ing resis­tance of mul­ti­ple TME fea­tures. Par­tic­u­lar atten­tion should be giv­en to gen­der bal­ance inclu­sion in order to inter­cept sex/gender dif­fer­ences and to deter­mine if there is an asso­ci­a­tion between sex/gender and treat­ment response.

Szczegółowy opis zakre­su tem­aty­cznego konkur­su zna­jdą Państ­wo w doku­men­tach: Call Text i Guide­lines for Appli­cants.